Outcomes research in glomerulonephritis

Seminars in Nephrology

Volumn 23, Issue 4, 2003, Pages 340-354

  Cattran, Daniel C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOCOSAHEXAENOIC ACID; ENALAPRIL; FISH OIL; HEPARIN; ICOSAPENTAENOIC ACID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIVE OIL; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; WARFARIN;

ADULT; ANAPHYLAXIS; BONE MARROW SUPPRESSION; CANCER SUSCEPTIBILITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EVIDENCE BASED MEDICINE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOTHERAPY; INFECTION; INFERTILITY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEMBRANOUS GLOMERULONEPHRITIS; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE BLIND PROCEDURE;

EID: 0041887448     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9295(03)00062-7     Document Type: Article

References (61)

1. Schena FP: Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 12:418-426, 1997
2. Maisonneuve P, Agodoa L, Gellert R, et al: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am J Kidney Dis 35:157-165, 2000
3. Glassock RJ: Secondary membranous glomerulonephritis. Nephrol Dial Transplant 7:64-71, 1992 (suppl 1)
4. D'Agati V: The many masks of focal segmental glomerulosclerosis. Kidney Int 46:1223-1241, 1994
5. Haas M, Meehan SM, Karrison TG, et al: Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30:621-631, 1997
6. O'Callaghan CA, Hicks J, Doll H, et al: Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol 33:157-165, 2002
7. Marx BE, Marx M: Prognosis of idiopathic membranous nephropathy: A methodologic meta-analysis. Kidney Int 51: 873-879, 1997
8. Cattran DC, Pei Y, Greenwood C: Predicting progression in membranous glomerulonephritis. Nephrol Dial Transplant 7:48-52, 1992 (suppl 1)
9. Hogan SL, Muller KE, Jennette JC, et al: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25:862-875, 1995
10. Heaf J, Lokkegaard H, Larsen S: The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997. Nephrol Dial Transplant 14:1889-1897, 1999
11. Simon P, Ramee MP, Autuly V, et al: Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int 46:1192-1198, 1994
12. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease: US Renal Data Systems; USRDS: 1999 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, 1999
13. Laluck BJ Jr, Cattran DC: Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33:1026-1032, 1999
14. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42:960-966, 1992
15. Cattran DC, Pei Y, Greenwood CM, et al: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51:901-907, 1997
16. Kobayashi Y, Tateno S, Shigematsu H, et al: Prednisone treatment of non-nephrotic patients with idiopathic membranous nephropathy. A prospective study. Nephron 30:210-219, 1982
17. Cattran DC, Delmore T, Roscoe J, et al: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320:210-215, 1989
18. Ponticelli C, Zucchelli P, Passerini P, et al: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48:1600-1604, 1995
19. Ponticelli C, Altieri P, Scolari F, et al: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444-450, 1998
20. Cattran DC, Appel GB, Hebert LA, et al: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59:1484-1490, 2001
21. Cameron JS, Healy MJ, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. QJM 74:133-156, 1990
22. Mathieson PW, Turner AN, Maidment CG, et al: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2:869-872, 1988
23. Stirling CM, Simpson K, Boulton-Jones JM: Immunosuppression and outcome in idiopathic membranous nephropathy. QJM 91:159-164, 1998
24. Torres A, Dominguez-Gil B, Carreno A, et al: Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61:219-227, 2002
25. Falk RJ, Hogan SL, Muller KE, et al: Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 116:438-445, 1992
26. Cattran DC, Greenwood C, Ritchie S, et al: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47:1130-1135, 1995
27. Fritsche L, Budde K, Farber L, et al: Treatment of membranous glomerulopathy with cyclosporin A: How much patience is required? Nephrol Dial Transplant 14:1036-1038, 1999
28. Miller G, Zimmerman R III, Radhakrishnan J, et al: Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 36:250-256, 2000
29. Choi MJ, Eustace JA, Gimenez LF, et al: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098-1114, 2002
30. Remuzzi G, Chiurchiu C, Abbate M, et al: Rituximab for idiopathic membranous nephropathy. Lancet 360:923-924, 2002
31. Sharma R, Sharma M, McCarthy ET, et al: Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 58:1973-1979, 2000
32. Carraro M, Caridi G, Bruschi M, et al: Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:1946-1952, 2002
33. Cameron JS, Turner DR, Ogg CS, et al: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213-218, 1978
34. Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72-79, 1998
35. Martinelli R, Okumura AS, Pereira LJ, et al: Primary focal segmental glomerulosclerosis in children: Prognostic factors. Pediatr Nephrol 16:658-661, 2001
36. Rydel JJ, Korbet SM, Borok RZ, et al: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25:534-542, 1995
37. Tune BM, Kirpekar R, Sibley RK, et al: Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up. Clin Nephrol 43:84-88, 1995
38. Ponticelli C, Villa M, Banfi G, et al: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34:618-625, 1999
39. Tarshish P, Tobin JN, Bernstein J, et al: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590-593, 1996
40. Waldo FB, Benfield MR, Kohaut EC: Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 6:503-505, 1992
41. Tufro-McReddie A, Alvarez E, Arrizurieta E, et al: Focal glomerulosclerosis in children: An Argentinian experience. Pediatr Nephrol 6:158-161, 1992
42. Cattran DC, Appel GB, Hebert LA, et al: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56:2220-2226, 1999
43. Ponticelli C, Edefonti A, Ghio L, et al: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326-1332, 1993
44. Meyrier A, Noel LH, Auriche P, et al: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 45:1446-1456, 1994
45. Lieberman KV, Tejani A: A randomized double blind placebo-controlled trial of cyclosporine in steroid resistant focal segmental glomerulosclerosis in children. J Am Soc Neph 7:56-63, 1996
46. Mitwalli AH: Adding plasmapheresis to corticosteroids and alkylating agents: Does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 13:1524-1528, 1998
47. Rauta V, Finne P, Fagerudd J, et al: Factors associated with progression of IgA nephropathy are related to renal function - a model for estimating risk of progression in mild disease. Clin Nephrol 58:85-94, 2002
48. Bartosik LP, Lajoie G, Sugar L, et al: Predicting progression in IgA nephropathy. Am J Kidney Dis 38:728-735, 2001
49. Pozzi C, Bolasco PG, Fogazzi GB, et al: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353:883-887, 1999
50. Kobayashi Y, Hiki Y, Kokubo T, et al: Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 72:237-242, 1996
51. Lai KN, Lai FM, Ho CP, et al: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 26:174-180, 1986
52. Welch TR, Fryer C, Shely E, et al: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121:474-477, 1992
53. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142-148, 2002
54. Roccatello D, Ferro M, Cesano G, et al: Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 15:833-835, 2000
55. Hamazaki T, Tateno S, Shishido H: Eicosapentanoic acid and IgA nephropathy. Lancet 1:1017-1018, 1984
56. Donadio JV Jr, Larson TS, Bergstralh EJ, et al: A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 12:791-799, 2001
57. Donadio JV Jr, Bergstralh EJ, Offord KP, et al: A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 331:1194-1199, 1994
58. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two-year prospective trial. Clin Nephrol 31:128-131, 1989
59. Pettersson EE, Rekola S, Berglund L, et al: Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 41: 183-190, 1994
60. Dillon JJ: Fish oil therapy for IgA nephropathy: Efficacy and interstudy variability. J Am Soc Nephrol 8:1739-1744, 1997
61. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254, 1994